Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 30

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 30
---
                                                                                          |
| Right to extend period to complete initial business combination |     | Our sponsor has the option to extend the completion window up to two times, each by an additional three months (for a total of up to 21 months to complete a business combination) without submitting such proposed extensions to our shareholders for approval or offering our public shareholders redemption rights in connection therewith by depositing into the trust account $0.10 per public share outstanding in connection with each such extension at any time following the closing of this offering and prior to the consummation of our initial business combination. The purchase price of the private units will be added to the net proceeds from this offering to be held in the trust account pending our completion of our initial business combination. If we do not complete our initial business combination within 15 months (or up to 21 months if the completion window is extended) from the closing of this offering, the proceeds of the sale of the private units and from any extension, if any, held in the trust account will be used to fund the redemption of our public shares (subject to the requirements of applicable law) and the private units will be worthless. |
| Expression of Interest                                          |     | The non-managing sponsor investors have expressed to us an interest in purchasing up to an aggregate of approximately $39.8 million of the units in this offering at the offering price (assuming the exercise in full of the underwriters’ over-allotment option), or up to 19.9% of this offering. None of the non-managing sponsor investors has expressed to us an interest in purchasing more than 9.9% of the units to be sold in this offering, except one non-managing sponsor investor has expressed to us an interest in purchasing 19.9% of the units to be sold in this offering. There can be no assurance that the non-managing sponsor investors will acquire any units, either directly or indirectly, in this offering, or as to the amount of the units the non-managing sponsor investors will retain, if any, prior to or upon the consummation of our initial business combination. Because these expressions of interest are not binding agreements or commitments to purchase, non-managing sponsor investors may determine to purchase fewer units in this offering, more units in this offering, or none at all. In addition, the underwriters have full discretion               |

18

| to allocate the units to investors and may determine to sell fewer units to the non-managing sponsor investors, or none at all, and the